Bradykinin B1 receptor antagonists: Expert Opinion on Therapeutic Patents: Vol 11, No 9

Views

CrossRef citations to date

Altmetric

Abstract

A series of basic, tripeptoid derivatives that are selective bradykinin B₁ receptor antagonists are claimed. These represent the first class of low molecular weight B₁ antagonists described and have the potential to be useful in treating inflammatory diseases and as antinociceptive agents. The basic template employed in these compounds offers considerable scope for optimisation to provide effective clinical candidates.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bradykinin B₁ receptor antagonists

Information for

Open access

Opportunities

Help and information

Bradykinin B1 receptor antagonists

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature

Bradykinin B₁ receptor antagonists